ANMAT issued a warning about the unauthorized sale of an experimental weight-loss drug.

The National Administration of Drugs, Foods and Medical Devices (ANMAT) in Argentina has issued a formal warning regarding the illegal sale of retatrutide, an experimental drug intended for weight loss. The regulatory body stated that the substance has not received official authorization for use or commercialization within the country.

Authorities emphasized that the drug is currently in the experimental phase and lacks the necessary safety and efficacy approvals required for public distribution. The alert serves to caution the public against purchasing or consuming the product, as its unauthorized status poses significant health risks due to the absence of regulatory oversight.